RIL
ACRS icon

Rothschild Investment LLC’s Aclaris Therapeutics ACRS Stock Holding History

Rothschild Investment LLC’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34 Buy
9
+1
+13% +$3 ﹤0.01% 3507
2025
Q4 		$24 Buy
+8
New +$20 ﹤0.01% 3328

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Rothschild Investment LLC's ACRS Position: Q1 2026 in Review

Rothschild Investment LLC increased its Aclaris Therapeutics (ACRS) stake by 13% in Q1 2026, buying an estimated $3 and bringing the position to 9 shares worth $34. The position accounts for ﹤0.01% of the portfolio, ranked #3507.

Rothschild Investment LLC first reported a position in ACRS in Q4 2025 and has held it in 2 quarters since. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Rothschild Investment LLC held 9 shares of Aclaris Therapeutics worth $34 as of Q1 2026.
  • Rothschild Investment LLC bought 1 Aclaris Therapeutics share in Q1 2026, an estimated $3.
  • Aclaris Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q1 2026, its #3507 holding.
  • Rothschild Investment LLC first reported a position in Aclaris Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Rothschild Investment LLC's 13F filing for Q1 2026, filed 7 May 2026.